Barclays PLC Has $5.87 Million Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Barclays PLC reduced its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 17.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,367 shares of the company's stock after selling 26,672 shares during the period. Barclays PLC owned approximately 0.21% of Twist Bioscience worth $5,873,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TWST. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $1,059,000. Principal Financial Group Inc. boosted its position in Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after purchasing an additional 82,953 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience in the third quarter valued at $3,302,000. Vanguard Group Inc. increased its position in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after buying an additional 189,791 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after buying an additional 9,722 shares during the last quarter.

Insiders Place Their Bets

In other news, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now directly owns 18,173 shares of the company's stock, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now owns 265,460 shares of the company's stock, valued at $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,432 shares of company stock worth $1,038,170. Insiders own 3.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TWST shares. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $52.80.

Twist Bioscience Stock Performance

TWST stock traded down $1.80 during midday trading on Wednesday, reaching $37.88. The company had a trading volume of 422,123 shares, compared to its average volume of 978,825. The firm has a market capitalization of $2.26 billion, a PE ratio of -11.21 and a beta of 2.34. The stock has a 50 day moving average price of $39.40 and a 200 day moving average price of $44.22. Twist Bioscience Co. has a fifty-two week low of $30.32 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the company earned ($0.75) earnings per share. The firm's revenue for the quarter was up 24.1% on a year-over-year basis. Analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.